You can buy or sell MGLN and other stocks, options, ETFs, and crypto commission-free!
Magellan Health, Inc. engages in the healthcare management business. It operates through the following segments: Healthcare, Pharmacy Management, and Corporate. Read More The Healthcare segment comprises of the Commercial and Government reporting units. The Pharmacy Management segment offers products and solutions that provide clinical and financial management of pharmaceuticals paid under both the medical and the pharmacy benefit.The Corporate segment covers amounts not allocated to the Healthcare and Pharmacy Management segments. The company was founded in 1969 and is headquartered in Scottsdale, AZ.
52 Week High
52 Week Low
Simply Wall StMar 12
How Should Investors React To Magellan Health, Inc.’s (NASDAQ:MGLN) CEO Pay?
Barry Smith has been the CEO of Magellan Health, Inc. (NASDAQ:MGLN) since 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we’ll look at a snap shot of the business growth. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. This process should give us an idea about how appropriately the CEO is paid. Check out our latest analysis for Magellan ...
Stock Price, News, & Analysis for Magellan Health
Magellan Health, Inc. provides healthcare management services in the United States. It operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine for health plans, care organizations, and employers. It also contracts with local, state, and federal governmental agencie...
Yahoo FinanceMar 11
Magellan Health Down Nearly 40%, in a Year: What's Next?
Magellan Health, Inc. MGLN seems to have fallen out of favor with investors on concerns surrounding the company owing to its subdued profitability and stiff competition limiting revenues. During fourth quarter results, the company reported an operating loss of 77 cents per share missing the Zacks Consensus Estimate of $1.42 per share. In the year ago quarter, the company reported earnings of $2.55 per share. Revenues of $1.84 billion also missed the Zacks Consensus Estimate of $1.89 billion. Segment prof...
Expected Apr 25, Pre-Market